0.591
price up icon3.67%   0.0209
 
loading
Allovir Inc stock is traded at $0.591, with a volume of 40,985. It is up +3.67% in the last 24 hours and down -23.74% over the past month. AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
See More
Previous Close:
$0.5701
Open:
$0.57
24h Volume:
40,985
Relative Volume:
0.15
Market Cap:
$68.63M
Revenue:
-
Net Income/Loss:
$-168.86M
P/E Ratio:
-0.3302
EPS:
-1.79
Net Cash Flow:
$-125.29M
1W Performance:
+6.87%
1M Performance:
-23.74%
6M Performance:
-25.74%
1Y Performance:
-62.12%
1-Day Range:
Value
$0.57
$0.591
1-Week Range:
Value
$0.5153
$0.6795
52-Week Range:
Value
$0.5153
$2.485

Allovir Inc Stock (ALVR) Company Profile

Name
Name
Allovir Inc
Name
Phone
(617) 433-2605
Name
Address
1100 WINTER STREET, WALTHAM
Name
Employee
112
Name
Twitter
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
ALVR's Discussions on Twitter

Compare ALVR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ALVR 0.5733 68.63M 0 -168.86M -125.29M -1.79
VRTX 446.42 115.74B 10.63B -479.80M -1.35B 13.33
REGN 738.52 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 586.49 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.16 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.51 24.49B 3.30B -501.07M 1.03B 11.54

Allovir Inc Stock (ALVR) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-19-21 Resumed Morgan Stanley Overweight
Aug-24-20 Initiated JP Morgan Overweight
Aug-24-20 Initiated Morgan Stanley Overweight
Aug-24-20 Initiated SVB Leerink Outperform

Allovir Inc Stock (ALVR) Latest News

pulisher
Nov 20, 2024

AlloVir falls after all-stock merger deal with Kalaris - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

AlloVir to combine with Kalaris Therapeutics in all-stock transaction - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

ROSEN, LEADING TRIAL ATTORNEYS, Encourages AlloVir, Inc. Investo - GuruFocus.com

Nov 20, 2024
pulisher
Nov 15, 2024

$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of IPXX, YOTA, IVCP and ALVR - GlobeNewswire Inc.

Nov 15, 2024
pulisher
Nov 15, 2024

AlloVir, Inc. (NASDAQ:ALVR) Sees Significant Drop in Short Interest - MarketBeat

Nov 15, 2024
pulisher
Nov 13, 2024

AlloVir Ditches Immunotherapy, Teams Up with Kalaris to Take Over the $14 Billion Retinal Market - BSA bureau

Nov 13, 2024
pulisher
Nov 12, 2024

Allovir stock plunges to 52-week low of $0.58 amid market challenges - Investing.com India

Nov 12, 2024
pulisher
Nov 12, 2024

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALVR, CDMO, EMKR on Behalf of Shareholders - cnhinews.com

Nov 12, 2024
pulisher
Nov 11, 2024

$hareholder Alert: The M&A Class Action Firm Launches Legal Inquiry the Merger ROIC, VINE, ALVR and CDMO - AccessWire

Nov 11, 2024
pulisher
Nov 11, 2024

AlloVir and Kalaris enter merger to advance retinal disease therapies - Pharmaceutical Technology

Nov 11, 2024
pulisher
Nov 11, 2024

AlloVir and Kalaris Therapeutics Announce Merger - FinSMEs

Nov 11, 2024
pulisher
Nov 10, 2024

$hareholder Alert: The M&A Class Action Launches Legal Inquiry for the Merger of ROIC, VINE, ALVR and CDMO - AccessWire

Nov 10, 2024
pulisher
Nov 09, 2024

ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc.ALVR - Business Wire

Nov 09, 2024
pulisher
Nov 09, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EMKR and ALVR on Behalf of Shareholders - GlobeNewswire

Nov 09, 2024
pulisher
Nov 09, 2024

ROIC, VINE, ALVR and CDMO Alert: The M&A Class Action Firm Continues to Investigate the Merger - AccessWire

Nov 09, 2024
pulisher
Nov 08, 2024

Items Tagged with 'TH-103' - BioWorld Online

Nov 08, 2024
pulisher
Nov 08, 2024

With Eylea rival in clinic, once-stealthy Kalaris finds public path via merger - BioCentury

Nov 08, 2024
pulisher
Nov 08, 2024

Items Tagged with 'Kalaris Therapeutics Inc.' - BioWorld Online

Nov 08, 2024
pulisher
Nov 08, 2024

Allovir sees a new direction with Kalaris merger - BioWorld Online

Nov 08, 2024
pulisher
Nov 08, 2024

SEC Form 425 filed by AlloVir Inc. - Quantisnow

Nov 08, 2024
pulisher
Nov 08, 2024

Kalaris to go public via reverse merger with AlloVir - BioPharma Dive

Nov 08, 2024
pulisher
Nov 08, 2024

AlloVir announces merger with Kalaris Therapeutics - The Pharma Letter

Nov 08, 2024
pulisher
Nov 08, 2024

Shareholder Alert: Ademi LLP Investigates Whether AlloVir, Inc. Is Obtaining a Fair Price for Its Public Shareholders - The Bakersfield Californian

Nov 08, 2024
pulisher
Nov 08, 2024

ALVR Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of AlloVir, Inc. Is Fair to Shareholders - Business Wire

Nov 08, 2024
pulisher
Nov 08, 2024

AlloVir and Kalaris Merge to Advance Retinal Therapies - TipRanks

Nov 08, 2024
pulisher
Nov 08, 2024

AlloVir and Kalaris Therapeutics To Merge - citybiz

Nov 08, 2024
pulisher
Nov 08, 2024

AlloVir Shares Slide Premarket on Reverse Merger With Kalaris Therapeutics - MarketWatch

Nov 08, 2024
pulisher
Nov 08, 2024

AlloVir stock falls after Kalaris merger deal (ALVR:NASDAQ) - Seeking Alpha

Nov 08, 2024
pulisher
Nov 08, 2024

AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina - The Manila Times

Nov 08, 2024
pulisher
Nov 08, 2024

AlloVir and Kalaris Therapeutics Announce Agreement for - GlobeNewswire

Nov 08, 2024
pulisher
Nov 05, 2024

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.05% - MSN

Nov 05, 2024
pulisher
Nov 02, 2024

Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for InvestorsContact The Gross Law Firm - GuruFocus.com

Nov 02, 2024
pulisher
Oct 30, 2024

Discovering Opportunities: AlloVir And 2 Other US Penny Stocks - Simply Wall St

Oct 30, 2024
pulisher
Oct 30, 2024

Shareholders that lost money on AlloVir, Inc.(ALVR) Urged to Joi - GuruFocus.com

Oct 30, 2024
pulisher
Oct 30, 2024

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir - GuruFocus.com

Oct 30, 2024
pulisher
Oct 29, 2024

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely - Simply Wall St

Oct 29, 2024
pulisher
Oct 29, 2024

AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors to - GuruFocus.com

Oct 28, 2024
pulisher
Oct 28, 2024

ROSEN, SKILLED INVESTOR COUNSEL, Encourages AlloVir, Inc. Invest - GuruFocus.com

Oct 28, 2024
pulisher
Oct 28, 2024

Respiratory Syncytial Virus Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | GSK, MedImmune, ReViral, Pfizer, Sanofi, BioComo, Merck - The Globe and Mail

Oct 28, 2024
pulisher
Oct 28, 2024

SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James - GuruFocus.com

Oct 28, 2024
pulisher
Oct 28, 2024

SHAREHOLDER ALERT: Levi & Korsinsky Notifies AlloVir, Inc.(ALVR) - GuruFocus.com

Oct 28, 2024
pulisher
Oct 28, 2024

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir - GuruFocus.com

Oct 28, 2024
pulisher
Oct 25, 2024

Allovir (ALVR) Sees 5.06% Stock Price Surge Amid Mixed Analyst R - GuruFocus.com

Oct 25, 2024
pulisher
Oct 23, 2024

Allovir CEO Diana Brainard sells $7,596 in stock - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

Allovir's general counsel Edward Miller sells $1,082 in stock By Investing.com - Investing.com South Africa

Oct 23, 2024
pulisher
Oct 23, 2024

Allovir's general counsel Edward Miller sells $1,082 in stock - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

Allovir's chief accounting officer Brett Hagen sells $746 in stock - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

Allovir CFO Vikas Sinha sells $2,649 in stock - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

Allovir CFO Vikas Sinha sells $2,649 in stock By Investing.com - Investing.com Canada

Oct 23, 2024

Allovir Inc Stock (ALVR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):